Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $19.00.

A number of equities analysts have commented on HALO shares. Piper Jaffray Companies boosted their price target on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, October 16th. Deutsche Bank set a $21.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research note on Wednesday. They issued a “neutral” rating and a $20.00 price target for the company. Finally, BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th.

Shares of Halozyme Therapeutics (NASDAQ HALO) traded up $0.02 during trading hours on Friday, reaching $18.94. 761,643 shares of the company traded hands, compared to its average volume of 1,495,665. The stock has a market capitalization of $2,690.00, a PE ratio of -27.85 and a beta of 2.09. Halozyme Therapeutics has a 12 month low of $10.79 and a 12 month high of $21.13. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). The firm had revenue of $63.73 million for the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. Halozyme Therapeutics’s revenue was up 100.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.23) EPS. equities analysts anticipate that Halozyme Therapeutics will post 0.26 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Halozyme Therapeutics by 4.8% in the 2nd quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock worth $148,652,000 after buying an additional 532,658 shares in the last quarter. Vanguard Group Inc. grew its stake in Halozyme Therapeutics by 9.5% in the 2nd quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after buying an additional 831,654 shares in the last quarter. BB Biotech AG lifted its holdings in shares of Halozyme Therapeutics by 6.7% in the 2nd quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock worth $105,961,000 after acquiring an additional 515,472 shares during the last quarter. Senzar Asset Management LLC lifted its holdings in shares of Halozyme Therapeutics by 17.1% in the 2nd quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock worth $52,399,000 after acquiring an additional 597,400 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Halozyme Therapeutics by 1.6% in the 2nd quarter. State Street Corp now owns 3,674,238 shares of the biopharmaceutical company’s stock worth $47,106,000 after acquiring an additional 59,566 shares during the last quarter. 84.33% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/26/halozyme-therapeutics-inc-halo-receives-average-rating-of-hold-from-brokerages.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.